Austrian Researchers
Find That Enzymes Restrict Out-of-Control Growth Factor Tied to Women's
Breast Cancer
SCOTTSDALE, Ariz., Oct. 4 /PRNewswire/ via NewsEdge Corporation -
As scientists seek
to unravel the many factors that lead to breast cancer, research in Austria
may have uncovered one small "chink in the armor" that could
soon lead to better health for women everywhere. Studies there have identified
a new way to normalize levels of Transforming Growth Factor-beta (TGF-beta),
a protein that is the culprit in many chronic, malignant conditions.
"In steady-state
amounts, TGF-beta plays an important role in the body's ability to repair
and heal itself," says Aftab Ahmed, Ph.D., Director of R&D and
Business Development at Marlyn Nutraceuticals. "However, research
has shown that excessive levels of TGF-beta trigger abnormal growths that
can give rise to malignancies."
Now researchers in
Austria have found that daily intake of systemic oral enzymes helps to
restrict TGF-beta within the healthy levels that the body requires. Drs.
Lucia Desser (Institute for Cancer Research, University of Vienna, Austria)
and Karl Ransberger (MUCOS Pharma, Munich, Germany) studied the effect
of systemic enzymes on TGF-beta levels, and found that enzymes consistently
brought these levels back into the normal range for their patients.
For more information
and results of the Austrian study, please contact Dr. Desser at Ldesser@hotmail.com.
Systemic enzymes are
gaining increased attention in the fight against cancer. Recently, the
FDA approved Marlyn's application for orphan drug status of Wobe-Mugos,
a systemic enzyme formulation used as an adjuvant therapy for multiple
myeloma. Earlier this year, the National Cancer Institute awarded a research
grant to Drs. Nicholas Gonzales and Linda Isaacs to study the effect of
systemic enzymes on pancreatic cancer. (Details about this study are available
at www.dr-gonzalez.com.)
Now the new Austrian
data indicate that systemic enzymes can also play an important role in
supporting women's health. Breast cancer strikes nearly 200,000 women
in the United States each year.
Systemic enzymes have
been used for decades to modulate the immune system and normalize inflammation.
Systemic enzymes work by breaking down harmful proteins, such as excess
TGF-beta. Several tens of scientific and clinical studies corroborate
the benefits of systemic enzymes in the maintenance of good health and
to better manage age-related afflictions and frailties.
The link between TGF-beta
and age-related health problems has long been recognized. The New England
Journal of Medicine recently cited a large body of research tying TGF-beta
to many age-related conditions (May 4, 2000 issue). Based on the Austrian
research, systemic enzymes offer a safe, wholesome solution for both men
and women looking to maintain optimal health with advancing age.
| 
